Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. 4SC AG
  6. Summary
    VSC   DE000A3E5C40

4SC AG

(VSC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
5.3(c) 5.19(c) 5.28(c) 5.36(c) 5.2(c) Last
3 616 100 0 1 908 83 Volume
0.00% -2.08% +1.73% +1.52% -2.99% Change
More quotes
Estimated financial data (e)
Sales 2021 1,40 M 1,64 M 1,64 M
Net income 2021 -28,0 M -32,8 M -32,8 M
Net cash position 2021 7,70 M 9,02 M 9,02 M
P/E ratio 2021 -1,91x
Yield 2021 -
Sales 2022 20,7 M 24,3 M 24,3 M
Net income 2022 -12,0 M -14,1 M -14,1 M
Net Debt 2022 2,60 M 3,05 M 3,05 M
P/E ratio 2022 -4,41x
Yield 2022 -
Capitalization 52,6 M 61,6 M 61,6 M
EV / Sales 2021 32,1x
EV / Sales 2022 2,67x
Nbr of Employees 43
Free-Float 26,0%
More Financials
Company
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The CompanyÔÇÖs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the... 
More about the company
Ratings of 4SC AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about 4SC AG
08/104Sc Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/194SC AG : REVERSE SPLIT: 1 of 5
FA
06/174SC Initiates Second Clinical Collaboration with the Netherlands Cancer Institute
CI
03/31SECTOR UPDATE : Health Care Stocks Nursing Moderate Gains
MT
03/31IMMUNIC : 4SC AG Sign IMU-838 Settlement Deal
MT
03/31PRESS RELEASE : Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obli..
DJ
03/234SC AG Provides Earnings Guidance for 2021
CI
03/234SC AG Auditor Raises 'Going Concern' Doubt
CI
20204SC AG Announces Positive Safety Review of Phase Ib/II EMERGE Study of domatinostat + a..
CI
20204Sc Ag Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
20204SC : provides Q1 2020 update
EQ
20204SC AG : Conference call to be hosted on 21 April 2020 to present the Q1 report 2020
EQ
20204SC AG : FDA Accepts IND Application for MERKLIN 2 Study
EQ
2020FDA Accepts 4SC AG's IND Application for MERKLIN 2 Study
CI
20204Sc Ag Reports Earnings Results for the Full Year Ended December 31, 2019
CI
More news
News in other languages on 4SC AG
09/16PTA-NEWS : 4SC AG: 4SC - Präsentationen klinischer Studien auf dem ESMO Kongress 2021
09/08PTA-NEWS : 4SC AG: 4SC - Präsentationen klinischer -2-
09/08PTA-NEWS : 4SC AG: 4SC - Präsentationen klinischer Studien auf dem 31. Deutschen Hautkrebs..
08/24PTA-NEWS : 4SC AG: 6 anstehende Konferenzen
08/10PTA-NEWS : 4SC AG: 4SC informiert über Q2 2021 und H1 2021
More news
Chart 4SC AG
Duration : Period :
4SC AG Technical Analysis Chart | VSC | DE000A3E5C40 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 5,20 €
Average target price 23,70 €
Spread / Average Target 356%
EPS Revisions
Managers and Directors
Jason Loveridge Chief Executive Officer
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Manfred RŘdiger Member-Supervisory Board
Helmut Jeggle Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
4SC AG0.00%64
MODERNA, INC.335.15%183 498
LONZA GROUP AG33.58%61 085
IQVIA HOLDINGS INC.46.38%50 254
CELLTRION, INC.-23.54%33 124
SEAGEN INC.-5.09%30 241